Literature DB >> 3304048

Mycobacterioses and the acquired immunodeficiency syndrome. Joint Position Paper of the American Thoracic Society and the Centers for Disease Control.

.   

Abstract

AIDS and HIV infection have now been recognized as conditions causing immunosuppression associated with an increased risk of mycobacterial disease, caused especially by M. avium complex and M. tuberculosis. In addition, disseminated disease due to other mycobacteria, heretofore considered nonpathogenic, is now being reported. The epidemiologic and clinical features of mycobacteriosis in patients with AIDS or HIV infection are unusual and distinctive. The high incidence of disseminated disease due to M. avium complex and the extent of infection, with abundant organisms in tissues and overwhelming mycobacteremia, is certainly unprecedented. Currently available treatment for this infection is unsatisfactory. The clinical features of tuberculosis in these patients with AIDS or HTLV III/LAV infection are often unusual, with a high frequency of extrapulmonary disease, and a relative infrequency of classical apical, cavitary disease in the lung. Nevertheless, tuberculosis in these individuals appears to respond to therapy and is potentially preventable. The interaction of tuberculous infection with HIV infection in the population has created new clinical syndromes that present a challenge to the diagnostic and therapeutic skills of clinicians.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3304048     DOI: 10.1164/ajrccm/136.2.492

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  27 in total

Review 1.  Management of nontuberculous mycobacterial infection in the elderly.

Authors:  Mehdi Mirsaeidi; Maham Farshidpour; Golnaz Ebrahimi; Stefano Aliberti; Joseph O Falkinham
Journal:  Eur J Intern Med       Date:  2014-03-29       Impact factor: 4.487

2.  Comparative evaluation of two commercial assays for direct detection of Mycobacterium tuberculosis in respiratory specimens.

Authors:  F Gamboa; J M Manterola; J Lonca; L Matas; P J Cardona; E Padilla; B Viñado; J Domínguez; A Hernández; V Ausina
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-03       Impact factor: 3.267

3.  A randomized comparison of two clarithromycin doses for treatment of Mycobacterium avium complex infections.

Authors:  B Dautzenberg; C Truffot-Pernot; J Hazebroucq; S Legris; C Guérin; C Begelman; G Guermonprez; M H Fievet; C Chastang; J Grosset
Journal:  Infection       Date:  1997 Jan-Feb       Impact factor: 3.553

Review 4.  The use of rifabutin in Europe for the treatment of mycobacterial infection in AIDS patients.

Authors:  B Dautzenberg
Journal:  Infection       Date:  1997 Jan-Feb       Impact factor: 3.553

Review 5.  Immunization against tuberculosis: what kind of vaccine?

Authors:  A J Crowle
Journal:  Infect Immun       Date:  1988-11       Impact factor: 3.441

6.  Mycobacterium kansasii and Pneumocystis carinii pneumonia in a patient with the acquired immunodeficiency syndrome.

Authors:  U Vurma-Rapp; F Colla; M Flepp
Journal:  Infection       Date:  1989 Mar-Apr       Impact factor: 3.553

7.  High prevalence of tuberculosis in AIDS patients in Spain.

Authors:  E Bouza; C Martín-Scapa; J C Bernaldo de Quirós; D Martínez-Hernández; J Menarguez; J Gómez-Rodrigo; J Cosín; M J Sagues-Cifuentes
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-12       Impact factor: 3.267

Review 8.  Repeated DNA sequences in mycobacteria.

Authors:  S Poulet; S T Cole
Journal:  Arch Microbiol       Date:  1995-02       Impact factor: 2.552

Review 9.  Tuberculosis: a health education imperative returns.

Authors:  G L White; B H Henthorne; S E Barnes; J T Segarra
Journal:  J Community Health       Date:  1995-02

Review 10.  Clarithromycin. A review of its pharmacological properties and therapeutic use in Mycobacterium avium-intracellulare complex infection in patients with acquired immune deficiency syndrome.

Authors:  L B Barradell; G L Plosker; D McTavish
Journal:  Drugs       Date:  1993-08       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.